Abcuro
Recent Financing
Series D
Recent Raise
$66M
Abcuro is a clinical-stage biotechnology company developing immunotherapies that selectively target and deplete highly cytotoxic T cells to treat rare autoimmune diseases.
Highlights
Focus Areas
Biotechnology
Health Care
Medical
Therapeutics
Recent Investors
Financials
$463M
Total Raised
4
Funding rounds
17
Investors